Security | Threat Detection | Cyberattacks | DevSecOps | Compliance

Metasploit now includes 6,000+ modules (exploits, payloads, scanners & post-modules). Used by over 80% of global pentesters as their primary exploit framework. Learn how to use Metasploit Framework, the most powerful penetration testing and ethical hacking tool used by cybersecurity professionals worldwide. What You’ll Learn in This Video.

Even the most mature organizations can stumble when it comes to SOC 2 compliance. In this video, we uncover the critical SOC 2 mistakes that even experienced teams make. Did You Know? Over 68% of companies fail their first SOC 2 audit due to documentation or evidence gaps. 46% of recurring SOC 2 issues stem from poor control mapping and risk assessment misalignment. If your business handles customer data, this video is essential to ensure you stay audit-ready, trustworthy, and compliant with AICPA’s Trust Service Criteria.

PCI DSS 4.0.1 is here — but do you really know what’s changed? While version 4.0 brought major updates to cardholder data protection, PCI DSS 4.0.1 isn’t a brand-new overhaul. Instead, it delivers crucial clarifications and refinements that every business handling credit card data needs to understand. Why it matters in 2025: Global payment card fraud losses are projected to exceed $38.5 billion by 2030.

Every year, businesses worldwide spend millions of dollars and countless hours on compliance audits — PCI DSS, GDPR, HIPAA, SOC 2, ISO 27001, DORA, SOX, CCPA… the list keeps growing. But here’s the problem: most organizations run these audits separately. That means: Multiple auditors Repeated testing Overlapping documentation Skyrocketing costs In fact, studies show that companies waste up to 40% of their compliance budgets on duplicated audit work. That’s not just expensive — it’s inefficient.

If your organization operates in pharmaceuticals, medical devices, biotech, or life sciences, you can’t afford to ignore FDA 21 CFR Part 11 compliance. In 2025, over 78% of FDA warning letters in pharma and clinical trials cited data integrity and Part 11 gaps – mainly missing audit trails, improper electronic signatures, and lack of validation.